Access to anti-retroviral drugs, female in Libya

Libya: Access to anti-retroviral drugs, female was 52.0% in 2023. ◆ Volatile

Latest (2023)
52.0%
Change on year
up 10.6%
World rank
116th
of 141 countries
All-time high
55.0%
in 2018
All-time low
3.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, female in Libya, 2000–2023

02040602000201120232000: 3 %2001: 3 %2002: 4 %2003: 5 %2004: 6 %2005: 9 %2006: 10 %2007: 13 %2008: 17 %2009: 22 %2010: 27 %2011: 32 %2012: 35 %2013: 35 %2014: 39 %2015: 45 %2016: 47 %2017: 49 %2018: 55 %2019: 52 %2020: 52 %2021: 50 %2022: 47 %2023: 52 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Libya is 52.0%, measured in 2023.

The figure is up 10.6% on the previous year and up 48.6% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Libya peaked at 55.0% in 2018 and was at its lowest, 3.0%, in 2000.

That places Libya 116th out of 141 countries with data for 2023, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Libya, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Libya, 2000 to 2023.
Year % Change
2000 3.0%
2001 3.0% +0.0%
2002 4.0% +33.3%
2003 5.0% +25.0%
2004 6.0% +20.0%
2005 9.0% +50.0%
2006 10.0% +11.1%
2007 13.0% +30.0%
2008 17.0% +30.8%
2009 22.0% +29.4%
2010 27.0% +22.7%
2011 32.0% +18.5%
2012 35.0% +9.4%
2013 35.0% +0.0%
2014 39.0% +11.4%
2015 45.0% +15.4%
2016 47.0% +4.4%
2017 49.0% +4.3%
2018 55.0% +12.2%
2019 52.0% -5.5%
2020 52.0% +0.0%
2021 50.0% -3.8%
2022 47.0% -6.0%
2023 52.0% +10.6%

Averages by decade

DecadeAverage LowestHighest Years
2000s 9.2% 3.0% 22.0% 10
2010s 41.6% 27.0% 55.0% 10
2020s 50.2% 47.0% 52.0% 4

Countries ranked near Libya

  1. 114 Latvia 54.0% compare
  2. 114 Venezuela, Bolivarian Republic of 54.0% compare
  3. 116 Armenia 52.0% compare
  4. 118 Belize 51.0% compare
  5. 118 Ghana 51.0% compare
  6. 118 Papua New Guinea 51.0% compare
  7. 118 South Sudan 51.0% compare

See the full ranking of 160 places →

More gender data for Libya

All data for Libya →

Frequently asked questions

What is access to anti-retroviral drugs, female in Libya?
Access to anti-retroviral drugs, female in Libya was 52.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Libya?
The highest recorded value was 55.0% in 2018.
What is the lowest access to anti-retroviral drugs, female recorded in Libya?
The lowest recorded value was 3.0% in 2000.
How does Libya rank for access to anti-retroviral drugs, female?
Libya ranks 116th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, female rising or falling in Libya?
Over the last ten years it is up 48.6%. The long-run trend across the full record is volatile.
Where does this Libya data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Libya. Statizoid, drawing on UNAIDS estimates. Retrieved 04 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/libya/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/libya/">Access to anti-retroviral drugs, female in Libya</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.